Trial Profile
Effects of clopidogrel vs prasugel vs ticagrelor on endothelial function, inflammatory and oxidative stress parameters and platelet function in patients undergoing coronary artery stenting. A randomised, prospective study.
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Clopidogrel (Primary) ; Prasugrel (Primary) ; Ticagrelor (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Pharmacodynamics
- Acronyms EST
- 03 Jan 2020 Results of Effects of clopidogrel vs prasugrel vs ticagrelor on endothelial function, inflammatory parameters, and platelet function in patients with acute coronary syndrome undergoing coronary artery stenting has been published in the European Heart Journal.
- 09 Mar 2016 Status changed from recruiting to discontinued as per European Clinical Trials Database record.
- 23 Feb 2016 Planned End Date changed from 1 Aug 2015 to 1 Jun 2016 as reported by ClinicalTrials.gov.